So here's a bit of good news for people dealing with psoriatic arthritis: there's a new oral treatment option coming to market. Bristol Myers Squibb Company (BMY) just won U.S. Food and Drug Administration approval for its drug Sotyktu to treat adults with the active form of the autoimmune disease. That gives patients another way to tackle the joint pain, skin issues, and overall inflammation that come with it.
The FDA made the call after looking at late-stage trial data that showed the drug worked better than a placebo at controlling the disease. For those keeping score at home, Sotyktu works by selectively going after something called tyrosine kinase 2—a pathway that's involved in the kind of inflammation driven by the immune system. It's a bit like finding a specific switch to turn down the body's overactive alarm system.
What the Trials Showed
Researchers put the drug through its paces in two big global Phase 3 studies, known as POETYK PsA-1 and POETYK PsA-2. Patients got either a daily 6-milligram tablet or a placebo during the controlled part of the trials. To measure how well it worked, they used the American College of Rheumatology response criteria, which is basically a standard way to check if a treatment is making a real difference.
By Week 16, about 54% of the patients taking Sotyktu hit what's called an ACR20 response in both studies. For comparison, only 34% and 39% of the placebo patients got there. That gap wasn't just noticeable—it was statistically significant, meaning it's very unlikely to be a fluke. The drug also looked good on other measures: about a quarter of the treated patients achieved an ACR50 response in the two studies. Plus, researchers saw meaningful improvements in minimal disease activity scores, suggesting broader relief across joints, skin, and patient-reported pain. In short, it helped people feel better in multiple ways.
Why This Matters to Bristol Myers and Patients
"Today's announcement marks the introduction of a new, differentiated option to treat adults with active psoriatic arthritis," said Al Reba, senior vice president of cardiovascular and immunology commercialization at Bristol Myers Squibb. He added, "This latest approval of Sotyktu confirms its important role in managing both skin and joint symptoms of psoriatic disease and is a key milestone as we continue to explore its development in diseases that have limited or no treatment options."
Dr. Philip J. Mease, director of rheumatology research at Providence Swedish Medical Center, also chimed in, noting that patients on the treatment showed better quality-of-life scores during the trials. So it's not just about lab numbers—it's about people actually living better.
